Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioInvent International AB ( (SE:BINV) ) has issued an update.
BioInvent International AB has sold its future royalty and milestone rights for the cancer drug mezagitamab to XOMA Royalty for up to USD 30 million. This transaction provides BioInvent with non-dilutive capital to advance its drug development programs and reflects XOMA’s increased interest in mezagitamab, enhancing its royalty portfolio with potential future earnings from the drug’s commercial success.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel antibodies for cancer immunotherapy. The company uses its proprietary technology platform to identify targets and antibodies, generating promising candidates for its clinical development pipeline and offering licensing opportunities.
Average Trading Volume: 101,277
Current Market Cap: SEK2.05B
For a thorough assessment of BINV stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue